Liposomal doxorubicin and nab-paclitaxel exhibit altered pharmacokinetics, efficacy, and toxicity compared to their parent compounds, providing insights for future nanoparticle-based therapies.
Liposomal doxorubicin and nab-paclitaxel are nanoparticle formulations of traditional cancer chemotherapy drugs which have ample clinical experience both pre- and post-nanoparticle modification. The alterations in pharmacokinetics, pharmacodynamics, efficacy, and toxicity compared with their parent compounds are instructive for future development of nanoparticle-based therapies. In this article we review the current status of these agents, emphasizing the alterations in clinical behavior resulting from the nanoparticle formulation of the parent compound.
Gaitanis et al. (Fri,) conducted a review in Cancer. Liposomal doxorubicin and nab-paclitaxel vs. Parent compounds was evaluated. Liposomal doxorubicin and nab-paclitaxel exhibit altered pharmacokinetics, efficacy, and toxicity compared to their parent compounds, providing insights for future nanoparticle-based therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: